Published in EMBO J on June 01, 1991
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet (2012) 4.70
Identification of fusion genes in breast cancer by paired-end RNA-sequencing. Genome Biol (2011) 2.64
Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer. Genes Chromosomes Cancer (2013) 1.23
Bringing the genomic landscape of small-cell lung cancer into focus. Nat Genet (2012) 0.94
Intrachromosomal rearrangements fusing L-myc and rlf in small-cell lung cancer. Mol Cell Biol (1991) 0.81
Complex intrachromosomal rearrangement in the process of amplification of the L-myc gene in small-cell lung cancer. Mol Cell Biol (1992) 0.78
New nucleotide sequence data on the EMBL File Server. Nucleic Acids Res (1991) 0.75
MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells. Oncotarget (2016) 0.75
A comprehensive set of sequence analysis programs for the VAX. Nucleic Acids Res (1984) 181.98
A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. Cell (1989) 21.54
Sequence-specific DNA binding by the c-Myc protein. Science (1990) 7.75
A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature (1986) 5.88
Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells. Mol Cell Biol (1984) 5.79
A non-AUG translational initiation in c-myc exon 1 generates an N-terminally distinct protein whose synthesis is disrupted in Burkitt's lymphomas. Cell (1988) 5.49
A new homeobox gene contributes the DNA binding domain of the t(1;19) translocation protein in pre-B ALL. Cell (1990) 5.39
The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature (1990) 5.24
Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science (1990) 5.20
L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature (1985) 4.66
Chromosomal translocation t(1;19) results in synthesis of a homeobox fusion mRNA that codes for a potential chimeric transcription factor. Cell (1990) 4.60
Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region. Science (1991) 4.45
Evolution of tumours and the impact of molecular oncology. Nature (1985) 4.24
PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell (1990) 3.98
Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science (1990) 3.34
Activation of cellular oncogenes in hemopoietic cells by chromosome translocation. Adv Cancer Res (1986) 2.84
Oncogene amplification in tumor cells. Adv Cancer Res (1986) 2.44
Negative autoregulation of c-myc transcription. EMBO J (1990) 2.38
The human myc gene family: structure and activity of L-myc and an L-myc pseudogene. Genes Dev (1987) 2.33
Human ret proto-oncogene mapped to chromosome 10q11.2. Oncogene (1989) 2.17
Structure and expression of the human L-myc gene reveal a complex pattern of alternative mRNA processing. Mol Cell Biol (1988) 1.78
The chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chimeric bcr/c-abl transcript. Mol Cell Biol (1986) 1.72
Establishment and characterisation of cell lines from patients with lung cancer (predominantly small cell carcinoma). Br J Cancer (1985) 1.52
Fused transcripts of c-myc and a new cellular locus, hcr in a primary liver tumor. Oncogene (1989) 1.33
The transforming activity of the chicken c-myc gene can be potentiated by mutations. Oncogene (1987) 1.24
Amplification of protooncogenes in surgical specimens of human lung carcinomas. Cancer Res (1989) 1.20
The human L-myc gene encodes multiple nuclear phosphoproteins from alternatively processed mRNAs. Mol Cell Biol (1988) 1.18
Expression and amplification of myc gene family in small cell lung cancer and its relation to biological characteristics. Cancer Res (1989) 1.10
myc family DNA amplification in small cell lung cancer patients' tumors and corresponding cell lines. Cancer Res (1988) 1.07
Transformation of murine myelomonocytic cells by myc: point mutations in v-myc contribute synergistically to transforming potential. Oncogene (1989) 0.97
Two N-myc polypeptides with distinct amino termini encoded by the second and third exons of the gene. Mol Cell Biol (1989) 0.94
Regulation of platelet-derived growth factor gene expression by transforming growth factor beta and phorbol ester in human leukemia cell lines. Mol Cell Biol (1987) 0.90
Rapid phosphorylation of the L-myc protein induced by phorbol ester tumor promoters and serum. EMBO J (1989) 0.87
myc genes and their deregulation in lung cancer. J Cell Biochem (1990) 0.77
Decay characteristics of HIV-1-infected compartments during combination therapy. Nature (1997) 13.68
The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell (2000) 8.95
Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature (1983) 8.18
Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med (2001) 7.78
Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A (1995) 7.11
Homogeneously staining chromosomal regions contain amplified copies of an abundantly expressed cellular oncogene (c-myc) in malignant neuroendocrine cells from a human colon carcinoma. Proc Natl Acad Sci U S A (1983) 7.01
Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science (1997) 6.37
Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature (1997) 5.43
A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J (1996) 5.33
Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science (1998) 5.07
Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol (1999) 5.02
Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J (2001) 4.70
Induction of c-fos-like protein in spinal cord neurons following sensory stimulation. Nature (1987) 4.59
Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A (1999) 4.52
Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med (2001) 4.50
Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A (1998) 4.48
Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell (1999) 4.38
Clinical applications of angiogenic growth factors and their inhibitors. Nat Med (1999) 4.26
Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J (1997) 4.07
Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J (2001) 3.88
Crystal structure of the conserved core of HIV-1 Nef complexed with a Src family SH3 domain. Cell (1996) 3.88
Identification of nuclear proteins encoded by viral and cellular myc oncogenes. Nature (1984) 3.86
PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat Cell Biol (2000) 3.81
Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci U S A (1998) 3.72
Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet (2000) 3.66
A cellular oncogene (c-Ki-ras) is amplified, overexpressed, and located within karyotypic abnormalities in mouse adrenocortical tumour cells. Nature (1983) 3.56
Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res (2001) 3.38
A license to kill. Cell (1996) 3.37
FGFR-4, a novel acidic fibroblast growth factor receptor with a distinct expression pattern. EMBO J (1991) 3.19
The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J (1995) 3.16
VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol (1999) 3.09
Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol (1995) 3.06
Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J (2001) 3.00
Vascular abnormalities and deregulation of VEGF in Lkb1-deficient mice. Science (2001) 2.99
Apoptosis in development. Nature (2000) 2.95
Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol (2001) 2.89
A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci U S A (2001) 2.88
Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem (1994) 2.87
Vascularization of the mouse embryo: a study of flk-1, tek, tie, and vascular endothelial growth factor expression during development. Dev Dyn (1995) 2.83
VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development (1996) 2.82
Induction of a basement membrane glycoprotein in embryonic kidney: possible role of laminin in morphogenesis. Proc Natl Acad Sci U S A (1980) 2.74
Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci U S A (1996) 2.71
PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat Cell Biol (2001) 2.70
Repression of cyclin D1: a novel function of MYC. Mol Cell Biol (1994) 2.67
Nucleotide sequence to the v-myc oncogene of avian retrovirus MC29. Proc Natl Acad Sci U S A (1983) 2.66
Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res (2000) 2.64
Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res (2000) 2.63
Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res (1998) 2.60
Metabolism of c-myc gene products: c-myc mRNA and protein expression in the cell cycle. EMBO J (1985) 2.53
Oncogene amplification in tumor cells. Adv Cancer Res (1986) 2.44
Fibronectin is produced by human macrophages. J Exp Med (1980) 2.44
VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol (1997) 2.43
A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains. Mol Cell Biol (1992) 2.34
Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci U S A (1998) 2.32
c-Myc-induced sensitization to apoptosis is mediated through cytochrome c release. Genes Dev (1999) 2.31
Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J Biol Chem (1998) 2.28
VEGFs, receptors and angiogenesis. Semin Cancer Biol (1999) 2.25
Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am J Pathol (2000) 2.24
Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci U S A (2001) 2.19
Isolation of the pericellular matrix of human fibroblast cultures. J Cell Biol (1979) 2.19
The human p50csk tyrosine kinase phosphorylates p56lck at Tyr-505 and down regulates its catalytic activity. EMBO J (1992) 2.16
A single amino acid in the SH3 domain of Hck determines its high affinity and specificity in binding to HIV-1 Nef protein. EMBO J (1995) 2.10
VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J (2000) 2.06
Tie receptors: new modulators of angiogenic and lymphangiogenic responses. Nat Rev Mol Cell Biol (2001) 2.05
Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo. Oncogene (1994) 2.05
FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. Cancer Res (1992) 1.99
A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities. J Biol Chem (1998) 1.98
Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer (1999) 1.97
Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res (2001) 1.95
A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J (1996) 1.95
Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. J Biol Chem (1999) 1.94
Biosynthesis of two subunits of type IV procollagen and of other basement membrane proteins by a human tumor cell line. Eur J Biochem (1980) 1.90
Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br J Cancer (1999) 1.87
Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. Am J Hum Genet (2000) 1.86
Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene (1997) 1.85
Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. Oncogene (1993) 1.83
Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost (1998) 1.80
Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. Curr Top Microbiol Immunol (1999) 1.79
Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. Blood (2000) 1.76
Differential expression of immediate early genes in the hippocampus and spinal cord. Neuron (1990) 1.76
Interactions of HIV-1 NEF with cellular signal transducing proteins. Front Biosci (2000) 1.75
Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors. Oncogene (1994) 1.73
Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin. Circ Res (2001) 1.71
Enhanced jun gene expression is an early genomic response to transforming growth factor beta stimulation. Mol Cell Biol (1989) 1.70
Alternative forms of Max as enhancers or suppressors of Myc-ras cotransformation. Science (1992) 1.70
Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors. Am J Pathol (1998) 1.66
Enhanced expression of the tie receptor tyrosine kinase in endothelial cells during neovascularization. Blood (1992) 1.65
Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. Lab Invest (1999) 1.62
The related FLT4, FLT1, and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells. J Exp Med (1993) 1.62
Refined assignment of the infantile neuronal ceroid lipofuscinosis (INCL, CLN1) locus at 1p32: incorporation of linkage disequilibrium in multipoint analysis. Genomics (1993) 1.61
Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol (1998) 1.61
Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts. Oncogene (1993) 1.61
Subcellular location of an abundant substrate (p36) for tyrosine-specific protein kinases. Mol Cell Biol (1983) 1.61
Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1. J Biol Chem (1999) 1.61
c-myc oncogene expression in colorectal cancer. Cancer (1987) 1.60
Identification of Tek/Tie2 binding partners. Binding to a multifunctional docking site mediates cell survival and migration. J Biol Chem (1999) 1.60
Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors. Am J Pathol (1995) 1.60